MedicaidPrior AuthLow impact
Fensolvi® (leuprolide acetate) subcutaneous syringe (New)
Humana·IN · Pediatrics, Endocrinology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Indiana Medicaid has established a new prior authorization policy for Fensolvi® (leuprolide acetate) subcutaneous syringe, effective January 1, 2026. This medication requires prior authorization for pediatric patients 2+ years old with central precocious puberty, with approvals granted for plan year durations.
Action Required
Before January 1, 2026: Billing team must update prior authorization workflows to include Fensolvi® (leuprolide acetate) subcutaneous syringe for Humana Indiana Medicaid members. Ensure providers document central precocious puberty diagnosis for patients 2+ years old before prescribing. Update pharmacy prior authorization request forms to include this medication. Claims will require prior authorization approval for coverage.